Background: Cerebral palsy is considered a neurological disorder and taking care of children with cerebral palsy is costly for their families. We evaluated the costs and complications of hospitalization, hoteling, treatment, paraclinic for children with cerebral palsy referring to Children's Medical Center in 2012. This study was an attempt to estimate the expenditures required for children with CP and to take a new attitude toward their lifetime quality. Methods: This retrospective cross-sectional study was conducted on 97 patients diagnosed with cerebral palsy and admitted in children's Medical Center in 2012. Data were gathered from the archives of the hospital. These data includes patients demographic characteristics like age, gender, causes of hospitalization, duration of hospitalization, total costs, treatment costs, paraclinical costs like echocardiography, tests, EEG, ECG, radiology and hoteling costs. The gathered information was analysed with SPSS, version 20. P value<0.05 was considered significant. Results: The mean cost attributed to hoteling, paraclinic, treatment and total costs were 5,276,865 Rials, 2,020,075 Rials, 2,496,668 Rials and 11,751,818 Rials, respectively. The average number of hospitalizations was 1.59 ± 1.45 with a maximum of 10 admissions in one year. The average duration of hospitalization in one year was 14.81 ± 12.23 with minimum and maximum of one and 91 d. The average of total costs per year was 48,396,556 ± 25,267,167. Conclusions: Evaluation the costs associated with this disorder would be helpful in determining required budget and facilitating the lifetime quality of patients and their families.
Fragile X syndrome (FXS) is caused by a mutation in the FMR1 gene which can lead to a loss or shortage of the FMR1 protein. This protein interacts with specific miRNAs, and a change can cause a range of neurological disorders. Therefore, miRNAs could act as a novel class of potential biomarkers for common CNS diseases. The aim of this study was to test this theory by exploring the expression profiles of various miRNAs in Iranian FXS patients using deep sequencing-based technologies, and validate the miRNAs affecting expression of the FMR1 gene. Blood samples were taken from 15 patients with FXS (9 males, 6 females) and 12 controls. 25 miRNAs were differentially expressed in individuals with FXS compared to controls. Levels of 9 miRNAs were found to be significantly changed (3 upregulated and 6 downregulated). In FXS patients, the levels of hsa-miR-532-5p, hsa-miR-652-3p and hsa-miR-4797-3p were significantly upregulated while levels of hsa-miR-191-5p, hsa-miR-181-5p, hsa-miR-26a-5p, hsa-miR-30e-5p, hsa-miR-186-5p, and hsa-miR-4797-5p exhibited significant downregulation; and these dysregulations were confirmed by RT‐qPCR. This study present altered miRNA expression in blood samples from FXS patients, which could be used for diagnostic, prognostic, and treatment purposes. Larger studies are required to confirm these preliminary results.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.